Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma

Clin Lymphoma Myeloma. 2007 Sep;7(8):541-5. doi: 10.3816/clm.2007.n.040.

Abstract

Subcutaneous panniculitis-like lymphomas (SPTCLs) are a heterogeneous group of diseases characterized by pleomorphic lymphocytes infiltrating the subcutis in a lobular panniculitis-like pattern. Characterization of SPTCL based on T-cell phenotype has prognostic significance in that most patients with the alpha/beta T-cell phenotype of SPTCL demonstrate clinically indolent behavior, whereas those with gamma/delta variant typically manifest more aggressive disease. In the past, traditional therapies have included single-agent or systemic multi-agent chemotherapy with or without radiation therapy, immunosuppressive therapies, or, in refractory patients, bone marrow transplantation. We describe complete clinical regression of disease and a median response duration of > 6 months in 2 patients with SPTCL treated with corticosteroids and denileukin diftitox. Furthermore, the addition of bexarotene to denileukin diftitox restored a clinical response in 1 of the patients after disease progression, suggesting the activity of this combination in patients with SPTCL.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Diphtheria Toxin / therapeutic use*
  • Humans
  • Interleukin-2 / therapeutic use*
  • Lymphoma, T-Cell, Cutaneous / diagnostic imaging
  • Lymphoma, T-Cell, Cutaneous / drug therapy*
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Male
  • Middle Aged
  • Panniculitis / diagnostic imaging
  • Panniculitis / drug therapy*
  • Panniculitis / pathology
  • Radiography
  • Recombinant Fusion Proteins / therapeutic use
  • Tomography, Emission-Computed
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Diphtheria Toxin
  • Interleukin-2
  • Recombinant Fusion Proteins
  • denileukin diftitox